ATE287730T1 - Arzneimittel zur anwendung bei tumorkrankheiten welches ro5-4864 und ein apoptoseauslöser enthält - Google Patents

Arzneimittel zur anwendung bei tumorkrankheiten welches ro5-4864 und ein apoptoseauslöser enthält

Info

Publication number
ATE287730T1
ATE287730T1 AT01929754T AT01929754T ATE287730T1 AT E287730 T1 ATE287730 T1 AT E287730T1 AT 01929754 T AT01929754 T AT 01929754T AT 01929754 T AT01929754 T AT 01929754T AT E287730 T1 ATE287730 T1 AT E287730T1
Authority
AT
Austria
Prior art keywords
medicinal product
tumor diseases
apoptosis
trigger
apoptosis trigger
Prior art date
Application number
AT01929754T
Other languages
English (en)
Inventor
Didier Decaudin
Guido Kroemer
Marie-France Poupon
Fariba Nemati
Arnaud Beurdeley-Thomas
Original Assignee
Centre Nat Rech Scient
Inst Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Inst Curie filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE287730T1 publication Critical patent/ATE287730T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01929754T 2000-04-28 2001-04-27 Arzneimittel zur anwendung bei tumorkrankheiten welches ro5-4864 und ein apoptoseauslöser enthält ATE287730T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0005438A FR2808197A1 (fr) 2000-04-28 2000-04-28 Utilisation du compose ro5-4864 et de composes derives pour la preparation de medicaments destines au traitement des pathologies tumorales
PCT/FR2001/001322 WO2001082969A2 (fr) 2000-04-28 2001-04-27 Medicaments destines au traitement des pathologies tumorales contenant le compose r05-4864 et un agent inducteur de l'apoptose

Publications (1)

Publication Number Publication Date
ATE287730T1 true ATE287730T1 (de) 2005-02-15

Family

ID=8849699

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01929754T ATE287730T1 (de) 2000-04-28 2001-04-27 Arzneimittel zur anwendung bei tumorkrankheiten welches ro5-4864 und ein apoptoseauslöser enthält

Country Status (10)

Country Link
US (1) US20030166598A1 (de)
EP (1) EP1276504B1 (de)
JP (1) JP2003531868A (de)
AT (1) ATE287730T1 (de)
AU (1) AU2001256440A1 (de)
CA (1) CA2407338A1 (de)
DE (1) DE60108622T2 (de)
ES (1) ES2234835T3 (de)
FR (1) FR2808197A1 (de)
WO (1) WO2001082969A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101917B2 (en) 2003-04-14 2006-09-05 Hoffmann-La Roche Inc. Mitochrondrial permeability transition pore affinity labels and modulators
WO2006020027A1 (en) * 2004-07-14 2006-02-23 Glycogenesys, Inc. Composition and method for treating hyperproliferative diseases
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CN117045655A (zh) * 2023-03-09 2023-11-14 兰州大学 喜树碱类衍生物在制备治疗膀胱癌药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58167514A (ja) * 1982-03-26 1983-10-03 Itaru Yamamoto 免疫調整剤
US4898861A (en) * 1987-03-26 1990-02-06 Hoffmann-La Roche Inc. Method for inhibiting the proliferation of tumor cells
WO1999056736A2 (en) * 1998-05-06 1999-11-11 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Apoptosis-inducing compounds
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
FR2779963A1 (fr) * 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer

Also Published As

Publication number Publication date
EP1276504A2 (de) 2003-01-22
ES2234835T3 (es) 2005-07-01
CA2407338A1 (fr) 2001-11-08
JP2003531868A (ja) 2003-10-28
EP1276504B1 (de) 2005-01-26
WO2001082969A3 (fr) 2002-04-18
US20030166598A1 (en) 2003-09-04
DE60108622D1 (de) 2005-03-03
DE60108622T2 (de) 2005-06-23
WO2001082969A2 (fr) 2001-11-08
FR2808197A1 (fr) 2001-11-02
AU2001256440A1 (en) 2001-11-12

Similar Documents

Publication Publication Date Title
GEP20237458B (en) Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
DE50310516D1 (de) Fredericamycin-derivate
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
HK1096392A1 (en) Substituted heterocycles
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
PA8529701A1 (es) Compuestos retinoides
MXPA06000464A (es) Uso de biotina o un derivado de biotina para aclarar la piel y tratar manchas por envejecimiento.
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
MY138883A (en) Use of asiatic acid for treatment of cencer
HK1078585A1 (en) Water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases
EP3811946A4 (de) Verwendung eines cdk4/6-inhibitors in kombination mit einem egfr-inhibitor bei der herstellung eines medikaments zur behandlung von tumorerkrankungen
EP1636160A4 (de) Neue therapeutische mittel zur behandlung von krebs, stoffwechselkrankheiten und hauterkrankungen
BR0112807A (pt) Derivados de indol e sua aplicação como medicamento
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
NZ524936A (en) Methods of inducing cancer cell death and tumor regression using a FTP inhibitor and a tyrosine kinase inhibitor
WO2002096348A3 (fr) Produit comprenant du mikanolide ou du dihydromikanolide en association avec un autre agent anti-cancereux
ZA200700945B (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
DE60115054D1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
ATE287730T1 (de) Arzneimittel zur anwendung bei tumorkrankheiten welches ro5-4864 und ein apoptoseauslöser enthält
ATE330626T1 (de) Arzneimittel zur immuntherapie maligner tumoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties